Allergy Treatment Market To Reach $ 40.360 Billion By End Of 2025

Allergy Treatment Market

The increasing demand for self-medication as well as the increasing prevalence of allergic diseases around the world complements the need for allergy treatment.

Allergy Treatment Market By Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis and Others), Treatment (Antiallergic Drugs and Immunotherapy), Dosage Form (oral, inhalers, intranasal) ”

– Allied market studies

NE WIN SIVERS DRIVE, PROVINCE: – PORTLAND, UNITED STATES, December 9, 2021 / — The global allergy treatment market was pegged at $ 24.65 billion in 2017 and is expected to reach $ 40.36 billion by 2025, registering a CAGR of 6.3% from 2018 to 2025. The report provides in-depth analysis of market dynamics, including drivers and restraints, major winning strategies, market size and projections, competitive landscape and major segments.

The increased prevalence of allergens and high tobacco consumption that can induce multiple allergies are driving the growth of the global allergy treatment market. However, the expiration of patents, competition from generic drugs, and the availability of alternative and complementary therapies are hampering market growth. On the contrary, the growing awareness of patients regarding food allergies is expected to create lucrative opportunities for market players in the coming years.

𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲 𝗢𝗳 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 @

𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗮𝗻𝗱 𝗽𝗿𝗼𝗳𝗶𝗹𝗲𝘀 𝗼𝗳 𝗺𝗮𝗷𝗼𝗿 𝗺𝗮𝗿𝗸𝗲𝘁 𝗽𝗹𝗮𝘆𝗲𝗿𝘀, 𝘀𝘂𝗰𝗵 𝗮𝘀

GlaxoSmithKline, ALK-Abelló A / S, Sallergenes Greer, Allergy Therapeutics, Sanofi SA, Johnson & Johnson, Merck Co. In, Merck KGaA, F. Hoffmann-La Roche AG and Allergan plc.


1) The Covid-19 pandemic, followed by containment, affected several manufacturing industries.
2) The prolonged containment has resulted in a disruption in the supply chain and an increase in the prices of raw materials.
3) However, as the world recovers from the pandemic, the market is expected to get back on track.

𝗖𝗼𝘃𝗶𝗱-𝟭𝟵 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗮𝘁:

The food allergy segment is expected to grow at the fastest CAGR of 8.3% during the forecast period, due to increased patient awareness of food allergies. However, the increased prevalence of allergic rhinitis across the world helped the rhinitis segment to gain the largest market share in 2017, accounting for around 40% of the total market share. Other segments analyzed in the report include asthma, skin allergies, food allergies and others.

In 2017, the anti-allergy segment captured around 89% of the market share, due to the growing trend towards over-the-counter (OTC) drugs for the treatment of allergic diseases. In addition, the segment is expected to continue to dominate the market. However, the immunotherapy treatment segment is expected to register the fastest CAGR of 8.5% during the forecast period, due to the growing awareness among healthcare professionals about the use of immunotherapy for treatment. allergies.

The intranasal sprays segment is estimated to register the fastest CAGR of 7.0% during the study period, as intranasal sprays offer a more promising approach to treat various allergic conditions. However, the oral drugs segment held the largest market share in 2017, contributing around 40% of total revenue, as oral drugs offer the convenience of self-administration, compactness, and ease of manufacture. The other dosage form discussed in the report includes inhalers.

✯ 𝗞𝗲𝘆 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗳𝗼𝗿 𝗦𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿𝘀

✦The study provides an in-depth analysis of the allergy treatment market along with current trends and future estimates to elucidate impending pockets of investment.

It offers an analysis of the Allergy Treatment market from 2018 to 2025, which is expected to enable stakeholders to capitalize on existing opportunities in the market.

✦A comprehensive analysis of four regions is provided to determine existing opportunities.

✦Profiles and growth strategies of key players are deeply analyzed to understand competitive prospects for the growth of the Global Allergy Treatment Market.

𝐏𝐫𝐨𝐜𝐮𝐫𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭? 𝐇𝐞𝐫𝐞:

𝗕𝗮𝘀𝗶𝗰 𝗣𝗹𝗮𝗻 | 𝗔𝗰𝗰𝗲𝘀𝘀 | 𝗬𝗲𝗮𝗿 𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗽𝘁𝗶𝗼𝗻 |

Sign up for the Avenue subscription to access over 12,000 company profiles and over 2,000 niche market research reports at $ 699 per month per seat. For one year, the customer must purchase a minimum package of 2 places.

14-day free trial request:

“We have also published some syndicated market research in the same area that you may be interested in. Below is the title of the report for your reference, considering the impact of Covid-19 on this market, which will help you assess the aftermath of the pandemic on the short and long term growth trends of this market. Marlet. “

𝗥𝗲𝗽𝗼𝗿𝘁𝘀 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 (𝗕𝗼𝗼𝗸 𝗡𝗼𝘄 𝘄𝗶𝘁𝗵 𝟭𝟬% 𝗗𝗶𝘀𝗰𝗼𝘂𝗻𝘁):

Sleeping Pills Market Industry Opportunities and Forecast, 2023
Telemedicine Market – Opportunity and Industry Forecast, 2030


Allied Market Research (AMR) is a full-service market research and business consulting arm of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global businesses as well as medium and small businesses with unmatched quality of “market research reports” and “business intelligence solutions”. AMR has a focused vision to provide business information and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market area.

Pawan Kumar, CEO of Allied Market Research, leads the organization towards delivering high quality data and information. We have professional relationships with various companies which helps us extract market data which helps us generate accurate research data tables and confirm the highest accuracy in our market forecast. Each of the data presented in the reports we publish is taken from primary interviews with senior officials of the main companies in the field concerned. Our secondary data sourcing methodology includes in-depth online and offline research and discussions with industry-savvy professionals and analysts.

David Corréa
Allied analytics srl
+1 503-894-6022
write us here
Visit us on social networks:

Comments are closed.